Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Non-Interventional Follow-Up to the VELOUR Study - Translational Research

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Prof Sabine Tejpar, Katholieke Universiteit Leuven
ClinicalTrials.gov Identifier:
NCT01754272
First received: December 12, 2012
Last updated: December 18, 2012
Last verified: December 2012
  Purpose

This is a follow-on study to the VELOUR trial (NCT00561470). The aim of this study is to acquire the archived colorectal cancer and metastasized tissue tumour blocks of patients who have participated in the VELOUR study.

These samples will be analysed to find proteins or markers which represent how an individual may be responding to treatment. The identification of these markers may help provide personalised and more effective treatment programs for patients with similar conditions in the future.


Condition
Metastatic Colorectal Cancer

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: A Non-Interventional Follow-Up to the VELOUR Study (Multicentre International Study of Aflibercept Versus Placebo in Combination With FOLFIRI for Metastatic Colorectal Cancer) - Translational Research

Resource links provided by NLM:


Further study details as provided by Katholieke Universiteit Leuven:

Primary Outcome Measures:
  • Primary colorectal cancer tumor blocks [ Time Frame: Two years ] [ Designated as safety issue: No ]
    Identify and acquire as many archived primary tumor blocks as possible of patients with mCRC treated in The VELOUR trial. Process the acquired samples as part of a translation research program.


Secondary Outcome Measures:
  • Metastatic tumor blocks [ Time Frame: Two years ] [ Designated as safety issue: No ]
    Identify and acquire as many archived metastatic tumor tissue blocks as possible of patients with mCRC treated in The VELOUR trial. Process the acquired samples as part of a translation research program.Process the acquired samples as part of a translation research program


Other Outcome Measures:
  • Residual blood samples [ Time Frame: Two years ] [ Designated as safety issue: No ]
    Acess as many residual blood samples (plasma, serum) collected in the frame of the VELOUR study as possible. Process the samples to determine markers relevant to angiogenesis factors, response to aflibercept and other markers which will be defined by the steering committee.


Biospecimen Retention:   Samples With DNA

Archived FFPE (Formaldehyde fixed paraffin-embedded) primary tumour colorectal cancer tissues Archived FFPE (Formaldehyde fixed paraffin-embedded) metastatic tumour tissue Archived residual blood samples (plasma, serum) collected in the frame of the VELOUR trial


Enrollment: 1226
Study Start Date: January 2012
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts
FOLFIRI + Aflibercept
Non-interventional study. No drugs administered. In this arm 612 patients from the VELOUR trial
FOLFIRI + Placebo
Non-interventional study. 614 patients from the FOLFIRI + placebo arm in the VELOUR trial.

Detailed Description:

The VELOUR trial (NCT00561470) has demonstrated the efficacy of aflibercept as a second line treatment in combination with fluorouracil, leucovorin, irinotecan (FOLFIRI)for metastatic colorectal cancer (mCRC) patients refractory to a first line oxaliplatin based chemotherapy regimen (Van Cutsem E., JCO 30 (2012):pp3499-3506). The FDA has approved Aflibercept (Zaltrap) for the treatment of metastatic colorectal cancer in combination with FOLFIRI on August 3rd 2012 and by European Medical Agency (EMEA) on November 15th 2012.

While the VELOUR study confirmed the benefits of using aflibercept in combination with FOLFIRI, the availability of biomarkers accurately predicting patients responding to this combination would further improve clinical utility of this drug. The molecular profiling of the Formaldehyde fixed paraffin embedded (FFPE) clinical tumor samples and serial plasma samples obtained from patients involved in VELOUR study and subsequent analysis of the molecular and clinical data would provide an invaluable opportunity to discover and potentially validate such biomarkers.

As blocks were not collected as part of the VELOUR trial, this protocol deals primarily with the steps that will be taken to gain ethics and consent in each of the participating countries and how the blocks will then be sourced and acquired, finally deposited in a biobank situated in KULeuven.

A VELOUR Translational Research Consortium (VTRC) has been formed by the Catholic University of Leuven (KULeuven)and Almac Diagnostics for the realisation of this study. The number of blocks available based on the surgical list held for the trial is estimated at 1030 (84% of complete trial cohort) and from a profiling viewpoint it has been calculated that the minimum number of blocks acceptable for processing and biomarker identification / validation is 500.

Due to the specific interest in angiogenesis, the VTRC consortium will aim to source blocks with both tumor and surrounding stromal tissue which will then be macro-dissected with the aim to generate data for both the tumor and surrounding angiogenic stroma. The project will generate gene expression, immunohistochemistry (IHC) and mutational data for these samples. In addition single nucleotide polymorphisms (SNP) data will be generated from non-tumor tissue, focusing on polymorphisms that demonstrate an association with disease or response outcome to therapy. Pre-processing and in silico evaluation of all data generated will support the outcome objectives of this study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with metastaic colorectal cancer who were refractory to an oxaliplatin-based chemotherapy.

Criteria

Inclusion Criteria:

  • Patients who have participated in the VELOUR trial

Exclusion Criteria:

  • Patients who have not participated in the VELOUR trial
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01754272

  Hide Study Locations
Locations
United States, Pennsylvania
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States, 19107
Australia, Western Australia
Sir Charles Gairdner Hospital
Nedlands, Western Australia, Australia, 6009
Austria
Medizinische Universität Wien
Wien, Austria, 1090
Belgium
UZ Leuven UZ Gasthuisberg 3000 Leuven
Leuven, Belgium, 3000
Brazil
Hospital Sírio E Libanês
Sao Paulo, Brazil, 01308050
Denmark
Odense Universitetshospital
Odense C, Denmark, 5000
Estonia
SA Põhja Eesti
Tartu, Estonia, 51014
Germany
Universitaetsklinikum Halle (Saale)
Halle, Germany, 06120
Greece
University Hospital Of Heraklion Voutes
Heraklion, Crete, Greece, 71110
Italy
IRCCS
Milano, Italy, 20133
Korea, Republic of
Asan Medical Center
Seoul, Korea, Republic of, 138-736
Samsung Medical Center Hematology and Oncology
Seoul, Korea, Republic of, 135-710
Netherlands
Orbis Medisch Centrum
Sittard-Geleen, Netherlands, 6162
Norway
Oslo Universitetssykehus HF
Oslo, Norway, 0407
Romania
Spitalul Universitar CF
Cluj Napoca, Romania, 400015
Russian Federation
NN Blokhin Russian Cancer Research Center
Moscow, Russian Federation, 115478
South Africa
Donald Gordon Medical Centre Wits University
Parktown, South Africa, 2193
Spain
Hospital Vall d'Hebrón
Barcelona, Spain, 08035
Sweden
Akademiska Sjukhuset Onkologiska Kliniken
Uppsala, Sweden, 751 85
United Kingdom
Mount Vernon Hospital
Greater London, United Kingdom, HA6 2RN
Sponsors and Collaborators
Katholieke Universiteit Leuven
Investigators
Principal Investigator: Sabine Tejpar, MD, PhD Katholieke Universiteit Leuven
  More Information

No publications provided

Responsible Party: Prof Sabine Tejpar, Professor, Katholieke Universiteit Leuven
ClinicalTrials.gov Identifier: NCT01754272     History of Changes
Other Study ID Numbers: ADX11080
Study First Received: December 12, 2012
Last Updated: December 18, 2012
Health Authority: Belgium: Ethics Committee

Keywords provided by Katholieke Universiteit Leuven:
metastatic colorectal cancer
mCRC
Aflibercept
FOLFIRI
translational research
retrospective
noninterventional
biomarkers
angiogenesis

Additional relevant MeSH terms:
Colorectal Neoplasms
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Neoplasms
Neoplasms by Site
Rectal Diseases

ClinicalTrials.gov processed this record on November 20, 2014